🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - https://www.thelancet.com/journals/lanonc/article/S1470-2045(26)00532-2/fulltext
3800 views · 102 likes · 58 reposts · 7 replies
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.org- soy nat@nataliaFHN
@_ShankarSiva @TROGfightcancer @TheLancetOncol What it means? SBRT in recurrence ( nodes) increase the OR survival?
- Lang Yang, MD@ynglng313674
@_ShankarSiva @TROGfightcancer @marklewismd MASTERPLAN's published protocol let bowel constraints override target coverage and excluded duodenal invasion. For bowel-adjacent tumors, that compromise is part of the regimen; reproducing 40 Gy/5 fractions alone would not reproduce its safety conditions.
- Stathis K@StathisKX
@_ShankarSiva @SprakerMDPhD @TROGfightcancer @TheLancetOncol “SBRT was delivered as 40 Gy in five fractions, with two to four fractions delivered per week, with real-time radiotherapy quality assurance.” What was the platform used to deliver real time QA?
- Shankar Siva@_ShankarSiva
@TROGfightcancer @marklewismd Sorry link didn’t work try this; https://www.sciencedirect.com/science/article/pii/S1470204526005322?dgcid=author
- Michiel Strijbos@StrijbosMichiel
@_ShankarSiva @TROGfightcancer @TheLancetOncol Incredibly impressive results, especially in such poor prognosis patients!
- Shankar Siva@_ShankarSiva
@TROGfightcancer 🧵 3/ Better efficacy without added harm. Grade 3+ adverse events remained stable between the SBRT (70%) and chemo-alone (64%) groups. 👏🏽👏🏽👏🏽Congratulations all investigators and patients involved! #ESMO26 @TROGfightcancer @marklewismd https://shorturl.at/0iefw
- Shankar Siva@_ShankarSiva
🧵2; 💥Tumor control ⬆️⬆️ gain in #PancreaticCancers with SBRT. Median PFS doubled (11.9 vs 6.3 months) and 12-month locoregional recurrence ⬇️⬇️ from 52.0% to 20.2%. #ESMO26 @TROGfightcancer https://shorturl.at/0iefw
Source: Shankar Siva · x.com